Effects of oral sildenafil on mortality in adults with PAH
Sponsored by Pfizer
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]). In addition, the relative effects on clinical worsening and 6-minute walking distance (6MWD) will be assessed.
Study Start Date: September 2014
Estimated Completion Date: June 2022
Internal Medicine: Epidemiology Family Medicine: Epidemiology
Drug: sildenafil citrate
Subjects ≥ 18 <75 years of age with any of the following conditions:
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.